#1 Clinical Trials Search in Europe

Batoprotafib

Batoprotafib, also known as TNO155, is an investigational drug currently being studied in clinical trials for the treatment of advanced solid tumors, particularly those with specific genetic mutations. This article explores the ongoing research into Batoprotafib’s potential as a targeted therapy for cancer patients, including its use alone and in combination with other treatments.

Table of Contents

What is BATOPROTAFIB?

BATOPROTAFIB, also known by its product code TNO155, is an innovative drug currently being studied for the treatment of advanced solid tumors with a specific genetic mutation called KRAS G12C[1]. It is being developed by Novartis Pharma AG and is currently in clinical trials to evaluate its safety and effectiveness.

How does BATOPROTAFIB work?

BATOPROTAFIB is designed to target tumors with the KRAS G12C mutation. KRAS is a gene that plays a crucial role in cell growth and division. When mutated, it can lead to uncontrolled cell growth, which is a hallmark of cancer. The G12C mutation is a specific alteration in the KRAS gene that is found in some types of cancer[1].

By specifically targeting this mutation, BATOPROTAFIB aims to inhibit the abnormal protein produced by the mutated KRAS gene, potentially slowing down or stopping the growth of cancer cells.

What conditions does BATOPROTAFIB treat?

BATOPROTAFIB is being studied for the treatment of several types of advanced solid tumors that harbor the KRAS G12C mutation, including:

  • Non-small cell lung cancer (NSCLC): A type of lung cancer that accounts for about 80-85% of all lung cancers[1].
  • Colorectal cancer: Cancer that starts in the colon or rectum[1].
  • Other advanced solid tumors with the KRAS G12C mutation[1].

Clinical Trials and Research

BATOPROTAFIB is currently being evaluated in clinical trials to assess its safety and efficacy. These trials are being conducted in multiple countries, including Hungary, France, Czechia, Italy, Germany, and Poland[1].

The ongoing research is focusing on several aspects:

  • Evaluating the safety and tolerability of BATOPROTAFIB when used alone or in combination with other drugs[1].
  • Determining the most effective dose and treatment regimen[1].
  • Assessing how well the drug works in shrinking tumors or slowing cancer growth (measured as Overall Response Rate or ORR)[1].
  • Investigating how the drug affects patients with brain metastases (cancer that has spread to the brain)[1].

Administration and Dosage

BATOPROTAFIB is available in the form of hard capsules and film-coated tablets, both of which are taken orally (by mouth)[1]. The exact dosage and treatment schedule are still being determined through clinical trials. It’s important to note that this medication should only be taken under the supervision of a healthcare professional and as part of a clinical trial at this time.

Potential Side Effects

As BATOPROTAFIB is still in the clinical trial phase, the full range of potential side effects is not yet known. The ongoing studies are carefully monitoring patients for any adverse reactions. Common side effects of cancer treatments may include fatigue, nausea, and changes in appetite, but the specific side effects of BATOPROTAFIB will be better understood as more data from the clinical trials becomes available[1].

Future Prospects

The development of BATOPROTAFIB represents an exciting advancement in targeted cancer therapy. By focusing on a specific genetic mutation, this drug has the potential to offer a more personalized approach to cancer treatment. However, it’s important to remember that BATOPROTAFIB is still in the research phase, and more studies are needed to fully understand its effectiveness and safety profile[1].

As research continues, BATOPROTAFIB may offer new hope for patients with advanced solid tumors harboring the KRAS G12C mutation, particularly those who have not responded to or are not eligible for other treatments[1].

Aspect Details
Drug Name Batoprotafib (TNO155)
Target Conditions Advanced solid tumors with KRAS G12C mutation, including NSCLC and colorectal cancer
Administration Oral (capsule or film-coated tablet)
Trial Phases Phase I/II integrated clinical trials
Key Objectives Assess safety, tolerability, determine optimal dosage, evaluate effectiveness
Combination Therapies Studied alone and in combination with other treatments (e.g., JDQ443, tislelizumab)
Primary Endpoints Safety, tolerability, overall response rate (ORR), overall intracranial response rate (OIRR)
Secondary Endpoints Anti-tumor activity, pharmacokinetics, immunogenicity, survival measures
Eligibility Patients with advanced solid tumors, specific genetic mutations, prior treatment history

FAQ

  • What is Batoprotafib? Batoprotafib, also known as TNO155, is an investigational drug being studied for the treatment of advanced solid tumors, especially those with specific genetic mutations like KRAS G12C.
  • What types of cancer is Batoprotafib being tested for? Batoprotafib is being tested for various advanced solid tumors, including non-small cell lung cancer (NSCLC), colorectal cancer, and other solid tumors with specific genetic mutations.
  • How is Batoprotafib administered? Batoprotafib is administered orally, either as a capsule or a film-coated tablet.
  • What are the main objectives of the clinical trials involving Batoprotafib? The main objectives include assessing the safety and tolerability of Batoprotafib, determining the appropriate dosage, and evaluating its effectiveness in treating advanced solid tumors, both alone and in combination with other drugs.
  • Who is eligible to participate in these clinical trials? Eligibility varies, but generally includes patients with advanced solid tumors who have specific genetic mutations (like KRAS G12C) and have received or are ineligible for standard treatments. Specific criteria may differ for each trial phase and group.

Ongoing Clinical Trials on Batoprotafib

  • Open‑label rollover study of JDQ443 for patients with KRAS G12C‑mutated non‑small cell lung cancer who continue to benefit from JDQ443 drug combination

    Not yet recruiting

    1 1 1 1
    Investigated drugs:
    Belgium Denmark France Italy Spain

  • Study of JDQ443, TNO155, and Tislelizumab for Patients with Advanced Solid Tumors with KRAS G12C Mutation

    Not recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Denmark France Germany Italy The Netherlands +1

Glossary

  • KRAS G12C mutation: A specific genetic change in the KRAS gene, which is often found in certain types of cancer and can affect how the cancer grows and responds to treatment.
  • Advanced solid tumor: A cancer that has spread from where it started to other areas of the body, forming solid masses or tumors.
  • Dose-limiting toxicity (DLT): Side effects of a drug that are severe enough to prevent an increase in dosage or require a reduction in dosage.
  • Maximum tolerated dose (MTD): The highest dose of a drug that can be given without causing unacceptable side effects.
  • Overall response rate (ORR): The percentage of patients whose cancer shrinks or disappears after treatment.
  • Progression-free survival (PFS): The length of time during and after treatment that a patient lives with cancer without it getting worse.
  • RECIST 1.1: Response Evaluation Criteria in Solid Tumors version 1.1, a standard way to measure how well a cancer patient responds to treatment.
  • Pharmacokinetics (PK): The study of how a drug moves through the body, including how it's absorbed, distributed, metabolized, and excreted.
  • Antidrug antibody (ADA): Antibodies produced by the body's immune system against a therapeutic drug, which can affect the drug's effectiveness or cause side effects.

References

  1. http://clinicaltrials.eu/trial/study-of-jdq443-tno155-and-tislelizumab-for-patients-with-advanced-solid-tumors-with-kras-g12c-mutation/